{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:18:40Z","timestamp":1771928320168,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:p>Current treatment options for acute and chronic pain provide limited efficacy and safety. There is an urgent need to develop drugs with new, non-opioid treatment strategies that produce fewer adverse consequences. Preclinical evidence across multiple models of acute and chronic pain demonstrate that (2R,6R)-Hydroxynorketamine [(2R,6R)-HNK], a nonhallucinogenic metabolite of ketamine, promotes potent and long-lasting analgesic effects. This review summarizes the growing evidence for the analgesic action of (2R,6R)-HNK in rodent models of acute and chronic pain. (2R,6R)-HNK produces antinociceptive effects in studies using standard tests for acute pain such as the hot plate test, although not in all studies, as well as reversal of mechanical hypersensitivity in models of acute pain like the carrageenan model (inflammatory pain). However, the most consistent anti-allodynic effects are seen in animal models aimed at mimicking chronic pain conditions, such as models of neuropathic pain (Spared Nerve Injury and Chemotherapy-induced peripheral neuropathy), low-back pain (disc puncture), complex regional pain syndrome type-1 (tibial fracture) and chronic primary pain (low-frequency percutaneous electrical nerve stimulation). Unlike ketamine, doses of (2R,6R)-HNK that counteract pain hypersensitivity do not cause sedation, dissociation, or sustain self-administration associated with abuse liability. Furthermore, distinct pharmacological effects of (2R,6R)-HNK, longer functional duration of action, non-opioid-mediated analgesia, and glutamatergic-mediated mechanisms, may distinguish (2R,6R)-HNK from ketamine and other analgesic drugs and contribute to the treatment of acute and chronic pain.<\/jats:p>","DOI":"10.3389\/fpain.2026.1749334","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:42:32Z","timestamp":1769755352000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The nonhallucinogenic ketamine metabolite (2R,6R)-hydroxynorketamine is a novel analgesic in animal models of pain"],"prefix":"10.3389","volume":"7","author":[{"given":"Bruno","family":"Carabelli","sequence":"first","affiliation":[{"name":"Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences","place":["Bethesda, MD, United States"]},{"name":"Henry M. Jackson Foundation for Military Medicine","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline A.","family":"Browne","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences","place":["Bethesda, MD, United States"]},{"name":"Henry M. Jackson Foundation for Military Medicine","place":["Bethesda, MD, United States"]},{"name":"Department of Biological Sciences, Munster Technological University","place":["Cork, Ireland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irwin","family":"Lucki","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences","place":["Bethesda, MD, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.11607\/ofph.1973","article-title":"Analgesic effects of intranasal ketamine in rat models of facial pain","volume":"32","author":"Claudino","year":"2018","journal-title":"J Oral Facial Pain Headache"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1038\/s41467-018-06295-x","article-title":"Ketamine reduces aversion in rodent pain models by suppressing hyperactivity of the anterior cingulate cortex","volume":"9","author":"Zhou","year":"2018","journal-title":"Nat Commun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.12688\/f1000research.11372.1","article-title":"Ketamine for pain","volume":"6","author":"Jonkman","year":"2017","journal-title":"F1000Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/AAP.0000000000000808","article-title":"Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American society of regional anesthesia and pain medicine, the American academy of pain medicine, and the American society of anesthesiologists","volume":"43","author":"Cohen","year":"2018","journal-title":"Reg Anesth Pain Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/pm\/pnx229","article-title":"Oral ketamine for acute pain management after amputation surgery","volume":"19","author":"Buvanendran","year":"2018","journal-title":"Pain Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pharmrev.120.000149","article-title":"Hydroxynorketamines: pharmacology and potential therapeutic applications","volume":"73","author":"Highland","year":"2021","journal-title":"Pharmacol Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2r,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B8","doi-asserted-by":"publisher","first-page":"108997","DOI":"10.1016\/j.jneumeth.2020.108997","article-title":"Animal models of pain: diversity and benefits","volume":"348","author":"Abboud","year":"2021","journal-title":"J Neurosci Methods"},{"key":"B9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/rapm-2018-000013","article-title":"Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain","volume":"44","author":"Kroin","year":"2019","journal-title":"Reg Anesth Pain Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1213\/ANE.0000000000006590","article-title":"A pharmacological evaluation of the analgesic effect and hippocampal protein modulation of the ketamine metabolite (2R,6R)-hydroxynorketamine in murine pain models","volume":"138","author":"Das","year":"2024","journal-title":"Anesth Analg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1124\/jpet.122.001278","article-title":"Antinociceptive and analgesic effects of (2R,6R)-hydroxynorketamine","volume":"382","author":"Yost","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"109276","DOI":"10.1016\/j.neuropharm.2022.109276","article-title":"(2R,6R)-hydroxynorketamine (HNK) reverses mechanical hypersensitivity in a model of localized inflammatory pain","volume":"221","author":"Yost","year":"2022","journal-title":"Neuropharmacology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/1440-1681.13737","article-title":"Intranasal (2R, 6R)-hydroxynorketamine for acute pain: behavioural and neurophysiological safety analysis in mice","volume":"50","author":"Goswami","year":"2023","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0301848","DOI":"10.1371\/journal.pone.0301848","article-title":"Effects of (2R,6R)-hydroxynorketamine in assays of acute pain-stimulated and pain-depressed behaviors in mice","volume":"19","author":"Hillhouse","year":"2024","journal-title":"PLoS One"},{"key":"B15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bcpt.12941","article-title":"Interactions of (2S,6S;2R,6R)-hydroxynorketamine, a secondary metabolite of (R,S)-ketamine, with morphine","volume":"122","author":"Lilius","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2313563","DOI":"10.1001\/jamanetworkopen.2023.13563","article-title":"Estimated rates of incident and persistent chronic pain among US adults, 2019\u20132020","volume":"6","author":"Nahin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.neuro.051508.135531","article-title":"Neuropathic pain: a maladaptive response of the nervous system to damage","volume":"32","author":"Costigan","year":"2009","journal-title":"Annu Rev Neurosci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1126\/science.288.5472.1765","article-title":"Neuronal plasticity: increasing the gain in pain","volume":"288","author":"Woolf","year":"2000","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17002","DOI":"10.1038\/nrdp.2017.2","article-title":"Neuropathic pain","volume":"3","author":"Colloca","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1067\/s1526-5900(03)00781-8","article-title":"Spared nerve injury model of neuropathic pain in the mouse: a behavioral and anatomic analysis","volume":"4","author":"Shields","year":"2003","journal-title":"J Pain"},{"key":"B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0304-3959(00)00276-1","article-title":"Spared nerve injury: an animal model of persistent peripheral neuropathic pain","volume":"87","author":"Decosterd","year":"2000","journal-title":"Pain"},{"key":"B23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.pain.2010.09.030","article-title":"Central sensitization: implications for the diagnosis and treatment of pain","volume":"152","author":"Woolf","year":"2011","journal-title":"Pain"},{"key":"B25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10194-023-01667-1","article-title":"The potent analgesia of intrathecal 2R, 6R-HNK via TRPA1 inhibition in LF-PENS-induced chronic primary pain model","volume":"24","author":"Liu","year":"2023","journal-title":"J Headache Pain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1574474","DOI":"10.3389\/fpain.2025.1574474","article-title":"Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mice","volume":"6","author":"Das","year":"2025","journal-title":"Front Pain Res (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jphs.2025.08.004","article-title":"(2r,6R)-hydroxynorketamine reverses mechanical and thermal pain hypersensitivity produced by the chemotherapeutic agent oxaliplatin in rats","volume":"159","author":"Campanile","year":"2025","journal-title":"J Pharmacol Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.brainres.2014.03.026","article-title":"Central antinociception induced by ketamine is mediated by endogenous opioids and \u03bc- and \u03b4-opioid receptors","volume":"1562","author":"Pacheco","year":"2014","journal-title":"Brain Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","article-title":"Antidepressant drugs act by directly binding to TRKB neurotrophin receptors","volume":"184","author":"Casarotto","year":"2021","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1038\/s41380-022-01673-w","article-title":"Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search","volume":"27","author":"Bonaventura","year":"2022","journal-title":"Mol Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1100","DOI":"10.1097\/PR9.0000000000001100","article-title":"Lessons learned in translating pain knowledge into practice","volume":"8","author":"Becker","year":"2023","journal-title":"Pain Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/cpt.3391","article-title":"A phase 1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-hydroxynorketamine in healthy volunteers","volume":"116","author":"Raja","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"106492","DOI":"10.1016\/j.phrs.2022.106492","article-title":"Glutamatergic systems in neuropathic pain and emerging non-opioid therapies","volume":"185","author":"Temmermand","year":"2022","journal-title":"Pharmacol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41582-020-0362-2","article-title":"Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities","volume":"16","author":"Davis","year":"2020","journal-title":"Nat Rev Neurol"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1749334\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:27:11Z","timestamp":1771925231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1749334\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":34,"alternative-id":["10.3389\/fpain.2026.1749334"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2026.1749334","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"1749334"}}